RESEARCH ARTICLE

Effect of High-Density Lipoprotein Metabolic Pathway Gene Variations and Risk Factors on Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in China

Qingyu Meng1,2,3☯, Lvzhen Huang1,2,3☯, Yaoyao Sun1,2,3, Yujing Bai1,2,3, Bin Wang1,2,3, Wenzhen Yu1,2,3, Mingwei Zhao1,2,3*, Xiaoxin Li1,2,3*

1 Peking University People’s Hospital, Ophthalmology Department, Beijing, China, 2 Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, China, 3 Beijing Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China

☯ These authors contributed equally to this work.
* zhaomingwei@medmail.com.cn (MZ); drlixiaoxin@163.com (XL)

Abstract

Purpose
To investigate the effect of genetic variants in the high-density lipoprotein (HDL) metabolic pathway and risk factors on neovascular age-related macular degeneration (nAMD) and polypoidal choroidal vasculopathy (PCV) in China.

Methods
A total of 742 Chinese subjects, including 221 controls, 230 cases with nAMD, and 291 cases with PCV, were included in the present study. Five single nucleotide polymorphisms (SNPs) from three genes in the HDL metabolic pathway (HDLMP) including cholesteryl ester transfer protein (CETP), hepatic lipase (LIPC) and lipoprotein lipase (LPL) were genotyped in all study subjects with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Risk factors including gender, hypertension, hyperlipidemia, diabetes mellitus, and coronary artery disease were identified. Chi-square tests or Fisher’s exact tests were applied to discover associations between SNPs and risk factors for PCV and nAMD. Gene-gene interactions and gene-environment interactions were evaluated by the multifactor-dimensionality reduction (MDR) method.

Results
CETP rs3764261 were significantly associated with an increased risk for PCV (odds ratio (OR) = 1.444, P = 0.0247). LIPC rs1532085 conferred an increased risk for PCV (OR = 1.393, P = 0.0094). We found no association between PCV and LPL rs12678919, LIPC rs10468017 or CETP rs173539. No association was found between five SNPs with nAMD.
Regarding risk factors, females were found to have significantly decreased risks for both PCV and nAMD (P = 0.006 and 0.001, respectively). Coronary artery disease (CAD) was a risk factor in PCV patients but played a protective role in nAMD patients. Hyperlipidemia was associated with PCV but not with nAMD. Neither hypertension nor diabetes mellitus was associated with PCV or nAMD. The MDR analysis revealed that a three-locus model with rs12678919, rs1532085, and gender was the best model for nAMD, while a five-locus model consisting of rs10468017, rs3764261, rs1532085, gender, and hyperlipidemia was best for PCV.

**Conclusion**

Our large-sample study suggested that CETP rs3764261 conferred an increased risk for PCV. We also first found the association between rs1532085 and PCV. The result of present study also showed that gender and CAD are associated with PCV and nAMD. Significant association was found between hyperlipidemia and PCV but not nAMD.

**Introduction**

Age-related macular degeneration (AMD) is the major cause of vision loss in the elderly in developed countries [1]. Advanced AMD consists of two forms: geographic atrophy (GA) of the retinal pigment epithelium (RPE) with overlying photoreceptors (called advanced “dry” AMD) and choroidal neovascularization (CNV, called “wet” AMD or neovascular AMD, nAMD). Polypoidal choroidal vasculopathy (PCV) is another important form of maculopathy found in a significant proportion of elderly Chinese and Japanese patients, and it manifests as orange-reddish nodules or polyp-like structures at the posterior pole [2]. Indocyanine green angiography (ICGA) can be used to definitively diagnose PCV. It has been observed that PCV and nAMD share some clinical and pathological features, such as demographics [3], risk factors [4], and manifestation [3]; however, whether PCV is a variant of CNV or is a distinctive disease characterized by an inner choroidal vascular abnormality also remains debatable.

Recently, two genome-wide association studies (GWAS) identified that genes in the high-density lipoprotein (HDL) cholesterol metabolic pathway were associated with AMD [5,6]. Some studies have identified genetic loci, such as rs10468017 near hepatic lipase (LIPC) and rs12678919 near lipoprotein lipase (LPL), were associated with late AMD [7–10], while other studies have found no association with nAMD [11,12]. However, results of replication studies in different cohorts on the reported HDL cholesterol metabolism genes, including the hepatic lipase (LIPC), cholesteryl ester transfer protein (CETP), and lipoprotein lipase (LPL) genes were inconsistent[13–15]. It is well documented that genotype-phenotype associations may vary in different populations; therefore, further investigations that attempt to replicate these associations in the Asian population.

As we know that, besides genetic factors, environment risk factors and lifestyles also participated in the development of AMD and PCV. However, due to the different ethnicities and lifestyles of individuals, the evidence and strength of such associations are widely variable [16–18]. Thus, we performed this study to investigate the effect between gene variations in the HDL cholesterol metabolic pathway and risk factors on nAMD and PCV in China.
Materials and Methods

Subjects

A total of 742 unrelated Chinese subjects were studied in this case-control cohort; specifically, 230 patients had nAMD, 291 patients had PCV, and 221 individuals without age-related maculopathy (ARM) were studied as controls. The study participants were recruited from the Department of Ophthalmology at the Peking University People’s Hospital, and the study was approved by the Ethical Committee of Peking University People’s Hospital. An informed consent process was established following the guidelines of the Helsinki Declaration, and all subjects signed consent forms. All subjects underwent a comprehensive ophthalmic examination, including visual acuity measurements, slit-lamp biomicroscopy, and dilated fundus examinations, performed by a retinal specialist. All cases with AMD and PCV underwent fluorescein angiography, optical coherence tomography (OCT), and indocyanine green angiograms with HRA2 (Heidelberg Engineering, Heidelberg, Germany). The diagnosis of AMD or ARM was defined in accordance with the International Classification System for ARM [19]. A PCV diagnosis was based on indocyanine green angiography (ICGA) results that showed a branching vascular network terminating in aneurysmal enlargements, which typify polypoidal lesions.

Exclusion criteria included any eye with any other macular abnormalities, such as pathological myopia, idiopathic choroidal neovascularization (CNV), presumed ocular histoplasmosis, angioid streaks, and any other secondary CNV. Normal controls were defined as having no clinical evidence of AMD or PCV in either eye or any other eye diseases, excluding mild age-related cataracts. Subjects with severe cataracts were excluded from the study. Information on hypertension, diabetes mellitus (DM), hyperlipidemia, and coronary artery disease (CAD) was obtained by a questionnaire.

Single Nucleotide Polymorphism Selection and Genetic Analysis

Five single nucleotide polymorphisms (SNPs) in three genes associated with AMD or PCV were selected according to the literature, which were rs10468017 in LIPC[5,6,20]; rs3764261 in CETP[5,6]; rs12678919 near LPL[5,6,20]. We also included LIPC rs1532085 and CETP rs173539, which regulated gene expression and showed impact on HDL levels[21,22]. Blood samples were collected from all participants and stored at -80°C before DNA extraction. Genomic DNA was extracted from venous blood leukocytes using a genomic extraction kit (Beijing eBios Biotechnology Co., Ltd.), and genotyping was performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS), as previously described [23]. Briefly, approximately 30 ng of genomic DNA was used to genotype each sample. The DNA samples were amplified, and the PCR products were used for locus-specific single-base extension reactions. The resulting products were desalted and transferred to a 384 SpectroCHIP array. Allele detection was performed using MALDI-TOF-MS. The mass spectromgrams were analyzed using MassARRAY Typer software version 4.0 (Sequenom, San Diego, CA, USA).

Statistical Analysis

The data were analyzed using SPSS (version 16.0; SPSS Science, Chicago, IL). All of the identified polymorphisms were assessed for Hardy-Weinberg equilibrium using chi-square tests. Single-marker association analyses were performed using chi-square tests or Fisher’s exact tests under various genetic models. Risk factors, including gender, hypertension, DM, hyperlipidemia, and CAD, were independently screened for associations between nAMD and PCV by applying chi-square tests or Fisher’s exact tests. Logistic regression models were used to calculate the odds ratio (OR) and 95% confidence interval (CI) of nAMD or PCV, with case groups
compared with the control group. Values of \( P < 0.05 \) were considered statistically significant. Joint effect analysis for of the significant SNPs identified from the main effects analysis \( (P < 0.05) \) was also performed to evaluated potential dose-response effects by adding up the number of alleles. To assess gene-gene interaction and gene-environment interactions, we employed the non-parametric multifactor dimensionality reduction (MDR) method [24,25]. We selected the model with the highest test accuracy and cross-validation consistency (CVC). We further evaluated the model using permutation testing 10,000 times, and we repeated the MDR analysis on each randomized dataset. This analysis was performed using nonparametric MDR software (version 2.0 alpha, www.multifactordimensionalityreduction.org).

**Results**

A total of 742 subjects participated in the study, including 221 control subjects (mean age ± standard deviation [SD], 67.2±9.6 years; 52.0% females), 230 cases with nAMD (mean age ± SD, 69.3±8.8 years; 36.5% females) in one or both eyes, and 291 cases with PCV (mean age ± SD, 66.6±9.6 years; 39.9% females) in at least one eye. The genders and ages of the controls and cases are provided in Table 1.

### Association between individual SNPs with nAMD and PCV

The genotype frequencies for patients and controls are shown in Table 2. No SNPs showed any significant deviation from Hardy-Weinberg equilibrium \( (P > 0.05) \), except CETP rs173539 in any groups and rs10468017 in nAMD group \( (P < 0.05) \) (Shown in S1 Table).

Regarding PCV, the risk allele (T) of CETP rs3764261 showed a strong association with an increased risk of PCV \( (OR = 1.444, 95\% CI 1.047–1.991, P = 0.0247) \), while CETP rs173539 showed no association with PCV \( (P = 0.930) \). The risk allele A of LIPC rs1532085 turned out to be a risk factor for PCV \( (OR = 1.393, 95\% CI 1.084–1.789, P = 0.0094) \). No significant association was found between the PCV group and LPL rs1257891 and LIPC rs10468017. However, among nAMD patients, we found no association with 5SNPs (all \( p > 0.5 \)).

### Association between environmental factors and nAMD and PCV

In our study, we found that females had significantly decreased risks of both PCV and nAMD \( (P = 0.006 \) and 0.001, respectively). CAD showed a risk effect in PCV patients \( (OR = 3.381, 95\% CI 1.377–8.302) \), but it played a protective role in nAMD patients \( (OR = 0.497, 95\% CI 0.268–0.922) \). Our analysis revealed that hyperlipidemia was significantly associated with PCV \( (OR = 3.099, 95\% CI 1.819–4.997, P = 0.000) \), but not nAMD. No association of hypertension and DM with PCV or nAMD was found.

| Table 1. Demographic Distribution of the study subjects. |
|---------------------------------------------|-------------|-------------|
|                | Controls (n = 221) | nAMD(n = 230) | PCV(n = 291) |
| Females, n (%) | 115(52.0)        | 84(36.5)     | 116(39.9)    |
| Age* range (Years) | 45–96       | 50–90     | 42–87       |
| Mean age ± SD** (Years) | 67.2±9.6 | 69.3±8.8 | 66.6±9.6 |

* Age of presentation.

** SD, standard deviation

nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.

doi:10.1371/journal.pone.0143924.t001
Association of the cumulative effects of the SNPs with nAMD and PCV

We also investigated potential dose-response and cumulative effects of the significant main-effect SNPs in a joint analysis. As shown in Table 3, the OR increased as the number of risk alleles for nAMD and PCV in individual patients increased (P = 0.024 and 0.048, respectively).

Gene-gene and gene-environment interactions

The five SNPs and environmental factors were included in the MDR analysis to assess their interaction. Table 4 summarizes the best joint risk factor interaction models obtained for PCV and nAMD. In models examining nAMD, the best overall model was the model assessing the joint effect of the three-locus model with rs12678919, rs1532085, and gender, yielding a perfect CVC and a test accuracy of 0.6074 (P = 0.0000). The second most predictive model was the single-locus model incorporating gender (CVC = 100, test accuracy = 0.5771, P = 0.0009). The combination of rs1532085 and gender was also predictive, with a CVC of 98 and a test accuracy of 0.5757 (P = 0.0018). Among the PCV models, we found that the five-locus model incorporating rs10468017, rs3764261, rs1532085, gender, and hyperlipidemia was the best model.

Table 2. Association between individual SNP and risk factors with nAMD and PCV risk.

| SNP      | Risk Allele | Control A1/A2 | PCV A1/A2 | nAMD A1/A2 | PCV vs Control OR (95%CI) P-value | nAMD vs Control OR (95%CI) P-value |
|----------|-------------|---------------|-----------|------------|----------------------------------|-----------------------------------|
| LPL rs12678919 | G           | 44/398        | 53/529    | 40/420     | 0.906 (0.595,1.38) 0.646          | 0.8615 (0.5495,1.351) 0.515        |
| LIPC rs10468017 | T           | 79/363        | 96/546    | 66/394     | 0.908 (0.654,1.259) 0.562          | 0.7697 (0.5388,1.1) 0.150          |
| LIPC rs1532085  | A           | 209/233       | 228/354   | 192/268    | 1.393 (1.064,1.789) **0.0094**     | 0.7987 (0.6139,1.039) 0.0938       |
| CETP rs173539   | T           | 26/416        | 35/547    | 40/240     | 1.024 (0.607,1.728) 0.930          | 1.524 (0.9132,2.543) 0.105         |
| CETP rs3764261  | T           | 71/371        | 126/456   | 86/374     | 1.444 (1.047,1.991) **0.0247**     | 1.202 (0.8505,1.697) 0.297         |
| Gender        | Female      | 115           | 116       | 84         | 0.611 (0.429, 0.870) **0.006**     | 0.530 (0.364, 0.773) **0.001**     |
|             | Hypertension| 143           | 183       | 134        | 0.924 (0.642, 1.330) 0.672         | 0.761 (0.520, 1.114) 0.160         |
|             | Diabetes Mellitus | 189       | 258       | 186        | 1.324 (0.786, 2.229) 0.292         | 0.716 (0.435, 1.178) 0.188         |
|             | Hyperlipidemia | 169          | 264       | 173        | 3.009 (1.819, 4.997) **0.000**     | 0.934 (0.607, 1.438) 0.756         |
|             | CAD         | 204           | 284       | 197        | 3.381 (1.377,8.302) **0.008**      | 0.497 (0.268, 0.922) **0.027**     |

nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy; SNP: single nucleotide polymorphism.

doi:10.1371/journal.pone.0143924.t002

Table 3. Association between the cumulative effects of the SNPs and nAMD and PCV risk.

| No. of risk alleles | Control | PCV | nAMD | ORa(95%CI) P | ORb(95%CI) P |
|---------------------|---------|-----|------|-------------|-------------|
| <= 1                | 37      | 23  | 18   | Ref         | Ref         |
| 2                   | 105     | 55  | 51   | 0.843(0.456, 1.557) 0.585 | 0.998(0.519, 1.922) 0.996 |
| 3                   | 147     | 104 | 100  | 1.138(0.639, 2.028) 0.661 | 1.398(0.754, 2.594) 0.288 |
| 4                   | 142     | 114 | 102  | 1.291(0.726, 2.297) 0.384 | 1.477(0.796, 2.739) 0.217 |
| 5                   | 60      | 50  | 54   | 1.341(0.706, 2.547) 0.371 | 1.850(0.944, 3.625) 0.073 |
| 6                   | 14      | 10  | 7    | 1.149(0.438, 3.013) 0.778 | 1.028(0.353, 2.990) 0.960 |
| >= 7                | 9       | 15  | 14   | 2.681(1.010, 7.120) 0.048 | 3.198(1.166, 8.772) 0.024 |

ORa, odds ratio of PCV to control
ORb, odds ratio of AMD to control
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.

doi:10.1371/journal.pone.0143924.t003
Table 4. Summary of Multifactor Dimensionality Reduction (MDR) results for interactions analysis on nAMD and PCV risk.

| Factors | MDR models | Testing accuracy | CVC | P     | OR (95% CI) | footnote |
|---------|------------|------------------|-----|-------|-------------|---------|
| nAMD risk |            |                  |     |       |             |         |
| 1       | Gender     | 0.5771           | 100/100 | 0.0009 | 1.8594 (1.1057, 3.1270) | BETTER |
| 2       | rs1532085, gender | 0.5757 | 97/100 | 0.0018 | 2.1212 (1.2558, 3.5832) | BETTER |
| 3       | rs12678919, rs1532085, gender | 0.6074 | 100/100 | 0.0000 | 2.5561 (1.5034, 4.3459) | BEST   |
| 4       | rs12678919, rs173539, rs1532085, gender | 0.5689 | 81/100 | 0.0060 | 2.9637 (1.7416, 5.0435) | BETTER |
| 5       | rs12678919, rs3764261, rs1532085, gender, hypertension | 0.5611 | 98/100 | 0.0018 | 3.9261 (2.2747, 6.7765) | BETTER |
| PCV risk |            |                  |     |       |             |         |
| 1       | Hyperlipidemia | 0.5580 | 98/100 | 0.0284 | 2.9376 (1.4407, 5.9896) | BETTER |
| 2       | rs1532085, hyperlipidemia | 0.5395 | 69/100 | 0.2421 | 2.9052 (1.6133, 5.2317) | X       |
| 3       | rs10468017, rs1532085, hyperlipidemia | 0.5508 | 91/100 | 0.0666 | 2.6466 (1.6024, 4.3712) | BETTER |
| 4       | rs10468017, rs1532085, gender, hyperlipidemia | 0.6325 | 100/100 | 0.0000 | 3.6203 (2.1397, 6.1254) | BETTER |
| 5       | rs10468017, rs3764261, rs1532085, gender, hyperlipidemia | 0.6195 | 100/100 | 0.0000 | 4.4125 (2.6154, 7.4443) | BEST   |

CVC—Cross-validation consistency
P-value based on 10,000 permutations
Best model with highest CVC and accuracy in bold.
nAMD: neovascular age-related macular degeneration; PCV: polypoidal choroidal vasculopathy.

overall, with a perfect CVC and a test accuracy of 0.6195 (P = 0.0000), while the next most predictive model, a four-locus model incorporating rs10468017, rs1532085, gender, and hyperlipidemia, was nearly as predictive.

Discussion

HDL metabolic pathway genes, including CETP, LIPC, and LPL, are identified by genome-wide studies and are associated with AMD. CETP facilitates the transfer of triglycerides from very-low-density lipoproteins and low-density lipoproteins to HDL in exchange for cholesterol ester [26]. CETP transports cholesterol from peripheral tissues to the liver and regulates the concentration of HDL cholesterol. CETP was found to be located in the interphotoreceptor matrix in the monkey retina and transfers oxidized lipids from the outer segments of the photoreceptors and other membranes to HDL-like lipoprotein particles, which are then internalized by the RPE and excreted back into the circulation through Bruch’s membrane [27]. Therefore, a dysfunction in CETP may lead to the accumulation of oxidized lipids, which contributes to the development of nAMD and PCV. Nakata, I. et al found that rs3764261 was significantly associated with PCV among Japanese population [28]. There was a significant association between rs3764261 and PCV in our study, which was consistent with previous study. These results indicated that rs3764261 was susceptible for PCV in Eastern Asian population. Liu et al [10] reported that CETP was a susceptible gene for nAMD (OR = 1.89, P = 1.82×10<sup>−4</sup>). The association was also significant in the result of GWAS and EWAS by Cheng et al [29] in East Asian population (P = 1.66×10<sup>−12</sup>). In the present study, the association between CETP rs3764261 and nAMD was in the same direction with these studies, although it did not reach a significant difference (OR = 1.202, P = 0.297). Several larger sample cohorts in Caucasian population also found a similar result that rs3764261 variant near CETP was associated with a non-significant increased risk of nAMD [12,20,30]. The two GWASs by Chen et al [6] in Japanese population and Nakata, I. et al [28] in the Caucasian population also indicated that CETP rs3764261 conferred increased risk for advanced AMD (OR = 1.19 and 1.12, respectively), but it did not reach the genome-wide significant (P = 7.4×10<sup>−7</sup> and 1.41×10<sup>−3</sup>, respectively). Our results are generally consistent with
theses previous studies. Larger sample studies are needed to verify the association between CETP rs3764261 and nAMD in Chinese population.

The hepatic lipase (LIPC) gene encodes hepatic triglyceride lipase, which has been shown to catalyze the hydrolysis of phospholipids, monoglycerides, diglycerides, triglycerides, and acyl-CoA thioesters, and it is a critical enzyme in HDL metabolism. In our study, we demonstrated for the first time that LIPC rs1532085 was associated with an increased risk for PCV. Rs1532085, located in the regulatory region of LIPC, is an eQTL of LIPC and cis-regulates LIPC expression [31]. It has been associated with HDL-C, total cholesterol, and triglyceride levels [32,33]. Furthermore, another gene-gene interaction study indicated that LIPC, especially the rs1532085 variant, might play a major role in the gene-gene interactions that regulate HDL-c levels [34]. Therefore, rs1532085 may participate in the development of PCV by regulating the HDL-C level.

LIPC rs10468017, located on chromosome 15 (15q21.3), has been studied with respect to its association with AMD. Several studies showed a decreased risk for AMD among Caucasians with the G allele of LIPC rs10468017 [5,7]. In contrast, two studies showed no association between AMD and rs10468017 in the Chinese population [11,12]. Our results did not reveal a significant association between nAMD or PCV and the rs10468017 SNP, which is consistent with the two case-control studies.

Regarding the lipoprotein lipase (LPL) gene, it encodes LPL and has the dual functions of facilitating triglyceride hydrolysis and serving as a ligand/bridging factor for receptor-mediated lipoprotein uptake. It also plays an important role in HDL metabolism. Results regarding the association between LPL and AMD are not consistent. One GWAS [5] and three case-control studies [12,13,15] revealed a non-significant decreased risk for AMD among G allele carriers of the rs12678919 variant. However, another study [6] found a significantly increased risk for AMD among G carriers. Our results for nAMD are consistent with the former researches, as we showed that there was a non-significantly decreased risk for nAMD among risk allele (G) carriers (OR = 0.8615, P = 0.515). For PCV, no association was found with rs12678919 in a Japanese study [28], which was consistent with our results (P = 0.646).

Our results demonstrated that being female played a protective role in both PCV and nAMD patients, and this association was significant. This finding has been reported elsewhere, and it has also been found that PCV is more common among males than females among Asians [35]. However, several studies have reported that the wet form of AMD is more common in women than in men [36,37]. The reason for this discrepancy could result from the higher smoking rates by men. As we know that, smoking is an important consistent risk factor for nAMD. Previous study found that persons who smoked were more likely to have PCV or CNV secondary to AMD than non-smokers [38]. In China, cigarette consumption has increased substantially since the 1980s, almost exclusively in men. In particular, the higher prevalence of smoking in men in Asia, and the stronger associations of smoking with PCV and CNV secondary to AMD [39]. Therefore, the high smoking rate by men could be an important confounder. Furthermore, female had independently increased odds of perceived unmet health care needs than male, which made it easier for men to be diagnosed for nAMD [40]. Large cohorts and further research are needed to confirm the role of gender in the development of nAMD and PCV.

Previous studies have revealed lipid deposition in the Bruch membrane and soft drusen, and the quantity of lipid was higher in the macula than in the peripheral area of human eyes [41]. Therefore, researchers have explored the important role of lipids in the pathogenesis of AMD. However, no association was found between serum lipid levels (HDL-C and total cholesterol levels) and AMD over a 20-year period based on data from three population-based cohort studies, namely, the Beaver Dam Eye Study (BDES), Blue Mountains Eye Study (BMES), and Rotterdam Study (RS) [42]. Our results also did not show any significant associations between
hyperlipidemia and nAMD. This finding suggests that the serum lipid level may not reflect the locally expressed lipid level in the retina. Moreover, it is not clear whether a high serum lipid level adversely regulates the expression of lipids in the retina. Zheng et al. used a high cholesterol diet and oral administrations of simvastatin to modulate serum cholesterol in mice. This study demonstrated that these treatments only modestly affected cholesterol content in the retina, but they had no significant effect on retinal expression of the major cholesterol- and vision-related genes [43]. Further research is needed to explore the relationship between lipid levels in the serum and the retina. Interestingly, we found a significant association between hyperlipidemia and PCV, which was previously rarely reported [44]. The finding of different associations of hyperlipidemia with PCV and nAMD suggests similar but not identical etiologies of the two diseases.

The possible association between CAD and AMD has previously been explored because they share a variety of risk factors, including smoking, hyperlipidemia, and chronic inflammatory processes at the site of pathogenesis [45–49]. However, the results from epidemiological studies and genetic analyses have been ambiguous. The meta-analysis by Usha Chakravarthy et al. revealed no significant association in the prospective cohort and the cross-sectional studies (RR 1.22, 95% CI 0.92–1.63 and OR 1.12; 95% CI 0.86–1.47), but a significant association was observed in the case-control studies, with an approximately two-fold increase in the probability of late AMD in individuals with cardiovascular disease (OR 2.20; 95% CI 1.48–3.26) [17]. In the Australian Heart Eye Study (AHES) [50], researchers reported that the severity of coronary stenosis and the presence of stenotic lesions of CAD were independently associated with early AMD but showed no associations with late AMD. However, an inverse association was reported between nAMD and cardiovascular disease requiring hospitalization in a large case-control study [51], which was in accordance with our results. We found that CAD conferred an increased risk for PCV (OR 3.381, 95% CI 1.377–8.302) and a decreased risk for nAMD (OR 0.497, 95% CI 0.262–0.992). Our results highlight the importance of monitoring individuals with evidence of CAD for signs of PCV. Furthermore, we speculated that if CAD patients get better as they receive treatment, their risk of nAMD would increase. Therefore, we recommend that patients with CAD who receive treatments also need to follow up for nAMD signs. Moreover, CAD patients have high mortality rate. 3.9% major adverse cardiac events, including death, myocardial infarction, and late revascularization, occurred at about 2.4 year follow-up [52]. Survival effect could be a confound factor in the analysis.

In our study, we did not find associations of hypertension or DM with patient group. Our results are not consistent with those of a meta-analysis [17], which showed that hypertension and DM were moderately associated with late AMD. Patients with PCV were reported to have a higher prevalence of hypertension, diabetes mellitus compared with controls in Japanese population [4]. But, no association was found between hypertension or DM and PCV in China [53]. A possible explanation for this discrepancy is the low awareness of these two diseases in China. The prevalence of hypertension was 29.6%, but the awareness rate was less than 50% in a national survey [54]. In northeastern China, approximately 8.2% of participants were diagnosed with DM, and the awareness rate was 64.1% [55]. According to the epidemiology studies above, we speculated that the actual number of patients with these two diseases is larger than that in our study. Summary of the impact of genetic variants and risk factors on nAMD and PCV between previous reports and this study were shown in S2 Table.

To assess the cumulative effects of SNPs in our study, we performed a joint analysis and found that the OR of PCV and nAMD patients increased with the number of risk alleles, indicating that these genes may act independently in the pathogenesis of PCV and nAMD. We also performed MDR analysis to explore gene-environment interactions. The MDR method collapses high-dimensional genotype predictors (i.e., SNPs) into a single dimension and provides
greater power to assess gene-gene and gene-environment interactions[56]. Regarding PCV patients, the best overall predictive model is the five-locus model incorporating rs10468017, rs3764261, rs1532085, gender, and hyperlipidemia, with perfect CVC and a high test accuracy, showing that the combination of CETP, LIPC, gender, and hyperlipidemia plays an important role in the development of PCV. Regarding nAMD, the combination of rs12678919, rs1532085, and gender is more predictive. The different models found to best predict PCV and nAMD indicate the different roles of the gene-environment interactions in the pathogenesis of these diseases. In our study, the testing accuracy of MDR analysis was approximately 0.6, which was insufficiently high. Therefore, to improve the testing accuracy, further studies using large samples are warranted to confirm these results.

There are several limitations of this study. One limitation is the sampled population. Because our study was conducted at a university hospital, which may have led to the inclusion of patients with more severe disorders compared with those in the general population. Second, smoking is not included in the risk factors analysis. Among environmental risk factors for AMD, active smoking is reported to be an important one. Overwhelming evidence showed that smokers have a greater prevalence of AMD than non-smokers in different ethnic population [38,44,57,58]. In non-smokers, people can also be exposed to the hazards of tobacco via passive smoking or secondhand smoking[59]. J C Khan et al[39] reported that passive smoking exposure was associated with an increased risk of AMD in non-smokers in a case-control study. The prevalence of passive smoking is as high as 30% in China in 2010[60]. However, the duration of passive smoking of Chinese is hard to define, as smoking in public place and at homes is quite common in China, which may easily cause recall bias for participants. Moreover, the cessation period differs a lot from months to years in former smokers. The diversity smoking status made it difficult to analyze the accurate association between smoking and nAMD and PCV. Considering the aforementioned circumstances, we did not include smoking in this study. However, based on the results of previous large cohorts, we believe that smoking is a risk factor for nAMD and PCV. Moreover, in our study, we did not analyze the association with lipids level and patients. Up to now, the data we collected was not large enough to perform the analysis, and we will report our results on this subject in future. Finally, there is the potential for residual confounding effects from unmeasured or unknown parameters, which were not adjusted for in this study.

In conclusion, the result of present study suggested that CETP rs3764261 was associated with PCV, and conferred a non-significantly increased risk for nAMD. We also first found the association between rs1532085 and PCV. Our study found that gender and CAD are associated with nAMD and PCV and that hyperlipidemia is a risk factor for PCV. The risk factors we found take more attention to nAMD or PCV patients who have CAD or hyperlipidemia.

Supporting Information

S1 Table. Hardy-Weinberg equilibrium.
(DOC)

S2 Table. Comparison of impact of genetic variants and risk factors on nAMD and PCV between previous reports and this study.
(DOCX)

Acknowledgments

The authors thank Yingjie Li (Department of Abdominal Surgical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College) and
Chunfang Zhang (Department of Clinical Epidemiology, Peking University People’s Hospital) for the support for data analysis.

Author Contributions
Conceived and designed the experiments: QYM LZH WZY MWZ XXL. Performed the experiments: QYM LZH YYS YJB BW. Analyzed the data: QYM LZH. Contributed reagents/materials/analysis tools: QYM LZH YJB BW. Wrote the paper: QYM LZH MWZ XXL.

References
1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY (2012) Age-related macular degeneration. Lancet 379: 1728–1738. doi:10.1016/S0140-6736(12)60282-7 PMID: 22559899
2. Yuzawa M, Mori R, Kawamura A (2005) The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol 89: 602–607. PMID:15834093
3. Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144: 15–22. PMID:17509509
4. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, et al. (2007) Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmology 114: 1722–1727. PMID:17400294
5. Neale BM, Fagerness J, Reynolds R, Sobrin L, Parker M, Raychaudhuri S, et al. (2010) Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc Natl Acad Sci U S A 107: 7395–7400. doi:10.1073/pnas.0912019107 PMID: 20385826
6. Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J, et al. (2010) Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A 107: 7401–7406. doi:10.1073/pnas.0912702107 PMID: 20385819
7. Lee J, Zeng J, Hughes G, Chen Y, Grob S, Zhao L, et al. (2013) Association of LIPC and advanced age-related macular degeneration. Eye (Lond) 27: 265–270; quiz 271.
8. Yu Y, Reynolds R, Rosner B, Daly MJ, Seddon JM (2012) Prospective assessment of genetic effects on progression to different stages of age-related macular degeneration using multistate Markov models. Invest Ophthalmol Vis Sci 53: 1548–1556. doi:10.1167/iovs.10-6851 PMID: 22247473
9. Yu Y, Bhangale TR, Fagermness J, Ripke S, Thorleifsson G, Tan PL, et al. (2011) Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. Hum Mol Genet 20: 3699–3709. doi:10.1093/hmg/ddr270 PMID: 21665990
10. Liu K, Chen LJ, Lai TY, Tam PO, Ho M, Chiang SW, et al. (2014) Genes in the high-density lipoprotein metabolic pathway in age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology 121: 911–916. doi:10.1016/j.ophtha.2013.10.042 PMID: 24393390
11. Tian J, Qin X, Fang K, Chen Q, Hou J, Li J, et al. (2012) Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population. Pharmacogenomics 13: 779–787. doi:10.2217/pgs.12.53 PMID: 22954510
12. Zhang X, Li M, Wen F, Zuo C, Chen H, Wu K, et al. (2013) Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population. Exp Eye Res 108: 16–22. doi:10.1016/j.exer.2012.12.005 PMID: 23274582
13. Fauser S, Smallhodzic D, Caramoy A, van de Ven JP, Kirchhof B, Hoying CB, et al. (2011) Evaluation of serum lipid concentrations and genetic variants at high-density lipoprotein metabolism loci and TIMP3 in age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 5525–5528. doi:10.1167/iovs.10-6827 PMID: 21613373
14. Tian J, Yu W, Qin X, Fang K, Chen Q, Hou J, et al. (2012) Association of genetic polymorphisms and age-related macular degeneration in Chinese population. Invest Ophthalmol Vis Sci 53: 4262–4269. doi:10.1167/iovs.11-5842 PMID: 22618592
15. Peter I, Huggins GS, Ordovas JM, Haan M, Seddon JM (2011) Evaluation of new and established age-related macular degeneration susceptibility genes in the Women’s Health Initiative Sight Exam (WHISE) Study. Am J Ophthalmol 152: 1005–1013. e1001. doi:10.1016/j.ajo.2011.03.018 PMID: 21906714
16. Klein R, Petos T, Bird A, Vannewkirk MR (2004) The epidemiology of age-related macular degeneration. Am J Ophthalmol 137: 486–495. PMID: 15013673
17. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. (2010) Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 10: 31. doi: 10.1186/1471-2415-10-31 PMID: 21144031

18. Cho BJ, Heo JW, Kim TW, Ahn J, Chung H (2014) Prevalence and risk factors of age-related macular degeneration in Korea: the Korea National Health and Nutrition Examination Survey 2010–2011. Invest Ophthalmol Vis Sci 55: 1101–1108. doi: 10.1167/iovs.13-13096 PMID: 24204048

19. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367–374. PMID: 7604360

20. Yu Y, Reynolds R, Fagerness J, Rosner B, Daly MJ, Seddon JM (2011) Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration. Invest Ophthalmol Vis Sci 52: 4663–4670. doi: 10.1167/iovs.10-7070 PMID: 21447678

21. Radovica I, Fridmanis D, Vaivade I, Nikitina-Zake L, Klovins J (2013) The association of common SNPs and haplotypes in CETP gene with HDL cholesterol levels in Latvian population. PLoS One 8: e64191. doi: 10.1371/journal.pone.0064191 PMID: 23675927

22. Suhy A, Hartmann K, Papp AC, Wang D, Sadee W (2015) Regulation of cholesteryl ester transfer protein expression by upstream polymorphisms: reduced expression associated with rs247616. Pharmacogenet Genomics 25: 394–401. doi: 10.1097/FCP.0000000000000151 PMID: 26061659

23. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M (2008) Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 54: 1637–1647. doi: 10.1373/clinchem.2008.103457 PMID: 18687736

24. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF, et al. (2001) Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 69: 138–147. PMID: 11404819

25. Xu HM, Sun WX, Qi T, Lin WY, Liu N, Lou XY (2014) Multivariate dimensionality reduction approaches to identify gene-gene and gene-environment interactions underlying multiple complex traits. PLoS One 9: e90103. doi: 10.1371/journal.pone.0090103 PMID: 25259984

26. Chapman MJ, Le Goff W, Guerin M, Kontush A (2010) Cholesteryl ester transfer protein: at the heart of cardiovascular disease. Circ Cardiovasc Genet 3: 365. doi:10.1161/CIRCGENETICS.110.948935 PMID: 20562444

27. Folkersten L, van’t Hooft F, Chernogubova E, Agardh HE, Hansson GK, Hedin U, et al. (2010) Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease. Circ Cardiovasc Genet 3: 365–373. doi: 10.1161/CIRCGENETICS.110.948935 PMID: 20562444

28. Merle BM, Maubaret C, Korbelnik JF, Deluyer MN, Rouger MB, Lambert JC, et al. (2013) Association of HDL-related loci with age-related macular degeneration and plasma lutein and zeaxanthin: the Alienor study. PLoS One 8: e79848. doi: 10.1371/journal.pone.0079848 PMID: 24223199

29. Altenhosen CD, Cockett PD, Vithana EN, Yeo IY, Wong D, Koh AH, et al. (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 29: 19–29. doi: 10.1016/j.preteyeres.2009.10.001 PMID: 19854291
36. Rudnicka AR, Jarrar Z, Wormald R, Cook DG, Fletcher A, Owen CG (2012) Age and gender variations in age-related macular degeneration prevalence in populations of European ancestry: a meta-analysis. Ophthalmology 119: 571–580. doi: 10.1016/j.ophtha.2011.09.027 PMID: 22176800

37. Joachim N, Mitchell P, Burlutsky G, Kifley A, Wang JJ (2015) The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study. Ophthalmology.

38. Age-Related Eye Disease Study Research G (2000) Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology 107: 2224–2232. PMID: 11097601

39. Khan JC, Thurby DA, Shahid H, Clayton DG, Yates JR, Bradley M, et al. (2006) Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol 90: 75–80. PMID: 16361672

40. Socias ME, Koehoorn M, Shoveller J (2015) Gender Inequalities in Access to Health Care among Adults Living in British Columbia, Canada. Womens Health Issues.

41. Holz FG, Sheraidah G, Pauleikhoff D, Bird AC (1994) Analysis of lipid deposits extracted from human macular and peripheral Bruch’s membrane. Arch Ophthalmol 112: 402–406. PMID: 8129668

42. Klein R, Myers CE, Buitendijk GH, Roithchina E, Gao X, de Jong PT, et al. (2014) Lipids, lipid genes, and incident age-related macular degeneration: the three continent age-related macular degeneration consortium. Am J Ophthalmol 158: 513–524.e513. doi: 10.1016/j.ajo.2014.05.027 PMID: 24879949

43. Zheng W, Mast N, Saadane A, Pikuleva IA (2014) Pathways of cholesterol homeostasis in mouse retina responsive to dietary and pharmacologic treatments. J Lipid Res.

44. Sun C, Klein R, Wong TY (2009) Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology 116: 1913–1919. doi: 10.1016/j.ophtha.2009.03.046 PMID: 19592102

45. Klein R, Klein BE, Tomany SC, Cruickshanks KJ (2003) The association of cardiovascular disease with the long-term incidence of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 110: 636–643. PMID: 12689879

46. Smith W, Mitchell P, Leeder SR, Wang JJ (1998) Plasma fibrinogen levels, other cardiovascular risk factors, and age-related maculopathy: the Blue Mountains Eye Study. Arch Ophthalmol 116: 583–587. PMID: 9596493

47. Klein R, Klein BE, Cruickshanks KJ (1999) The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res 18: 371–389. PMID: 10192518

48. Klein R, Klein BE, Cruickshanks KJ (2003) Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 27: 1355–1361. doi: 10.1093/ajh/hpu053 PMID: 12869879 – 1361. doi:10.1093/ajh/hpu053 PMID: 24698853

49. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P (2008) Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 92: 509–512. doi: 10.1136/bjo.2007.131706 PMID: 18310310

50. Wang SB, Mitchell P, Chiha J, Liew G, Plant AJ, Thiagalingam A, et al. (2014) Severity of coronary artery disease is independently associated with the frequency of early age-related macular degeneration. Br J Ophthalmol.

51. Nguyen-Khoa BA, Goehringer EL Jr, Werther W, Gower EW, Do DV, Jones JK (2008) Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol 126: 1280–1286. doi: 10.1001/archoph.126.9.1280 PMID: 18779491

52. Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG (2015) Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ 351: h4984. doi: 10.1136/bmj.h4984 PMID: 26432468

53. Cackett P, Yeo I, Cheung CM, Vithana EN, Wong D, Tay WT, et al. (2011) Relationship of smoking and cardiovascular risk factors with polypoidal choroidal vasculopathy and age-related macular degeneration in Chinese persons. Ophthalmology 118: 846–852. doi: 10.1016/j.ophtha.2010.09.026 PMID: 21146223

54. Wang J, Zhang L, Wang F, Liu L, Wang H, China National Survey of Chronic Kidney Disease Working G (2014) Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens 27: 1355–1361. doi: 10.1093/ajh/hpu053 PMID: 24698853

55. Wang C, Yu Y, Zhang X, Li Y, Kou C, Li B, et al. (2014) Awareness, treatment, control of diabetes mellitus and the risk factors: survey results from northeast China. PLoS One 9: e103594. doi: 10.1371/journal.pone.0103594 PMID: 25068894

56. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 19: 376–382. PMID: 12584123
57. Jonasson F, Fisher DE, Eiriksdottir G, Sigurdsson S, Klein R, Launer LJ, et al. (2014) Five-year incidence, progression, and risk factors for age-related macular degeneration: the age, gene/environment susceptibility study. Ophthalmology 121: 1766–1772. doi: 10.1016/j.ophtha.2014.03.013 PMID: 24768241

58. Cheung CM, Li X, Cheng CY, Zheng Y, Mitchell P, Wang JJ, et al. (2014) Prevalence, racial variations, and risk factors of age-related macular degeneration in Singaporean Chinese, Indians, and Malays. Ophthalmology 121: 1598–1603. doi: 10.1016/j.ophtha.2014.02.004 PMID: 24661862

59. Nishino Y, Tsuji I, Tanaka H, Nakayama T, Nakatsuka H, Ito H, et al. (2014) Stroke mortality associated with environmental tobacco smoke among never-smoking Japanese women: a prospective cohort study. Prev Med 67: 41–45. doi: 10.1016/j.ypmed.2014.06.029 PMID: 24983889

60. Yang S, He Y, Liu M, Wang Y, Wu L, Wang J, et al. (2015) Changes in and patterns of smoking exposure in an elderly urban population in Beijing: 2001–2010. PLoS One 10: e0118500. doi: 10.1371/journal.pone.0118500 PMID: 25785722